Literature DB >> 17280502

Gene-expression analysis and the basal-like breast cancer subtype.

Timothy J Finnegan1, Lisa A Carey.   

Abstract

Analysis of the patterns of gene expression in breast cancer suggests that it is not a single entity, but is comprised of several biologically distinct subtypes with characteristic molecular profiles. These molecular profiles confirm the clinical impression that estrogen receptor (ER)-negative differs from ER-positive, and expands our understanding by identifying breast cancer subtypes, including the basal-like and human epidermal growth factor receptor (HER)2/ER subtypes within the ER-negative subset, and the luminal A and B subtypes within ER-positive disease. The basal-like subtype is characterized by the low expression levels of the ER-related and the HER2-related group of genes, and therefore is often 'triple negative' on clinical assays for these proteins. This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280502     DOI: 10.2217/14796694.3.1.55

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  13 in total

1.  ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.

Authors:  Glauco Baiocchi; Ademar Lopes; Renata A Coudry; Benedito M Rossi; Fernando A Soares; Samuel Aguiar; Gustavo C Guimarães; Fabio O Ferreira; Wilson T Nakagawa
Journal:  Int J Colorectal Dis       Date:  2009-04-24       Impact factor: 2.571

2.  Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

Authors:  Maria J Sambade; J Terese Camp; Randall J Kimple; Carolyn I Sartor; Janiel M Shields
Journal:  Radiother Oncol       Date:  2009-10-23       Impact factor: 6.280

3.  Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.

Authors:  Gangarao Davuluri; William P Schiemann; Edward F Plow; Khalid Sossey-Alaoui
Journal:  JAKSTAT       Date:  2015-02-03

Review 4.  Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis.

Authors:  Khalid Sossey-Alaoui
Journal:  Semin Cell Dev Biol       Date:  2012-10-29       Impact factor: 7.727

Review 5.  Elucidating the molecular signaling pathways of WAVE3.

Authors:  Urna Kansakar; Wei Wang; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Ann Transl Med       Date:  2020-07

6.  miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.

Authors:  Katarzyna Augoff; Brian McCue; Edward F Plow; Khalid Sossey-Alaoui
Journal:  Mol Cancer       Date:  2012-01-30       Impact factor: 27.401

7.  Transcriptomic landscape of breast cancers through mRNA sequencing.

Authors:  Jeyanthy Eswaran; Dinesh Cyanam; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Suresh B Pakala; Sujit S Nair; Liliana Florea; Suzanne A W Fuqua; Sucheta Godbole; Rakesh Kumar
Journal:  Sci Rep       Date:  2012-02-14       Impact factor: 4.379

8.  Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer.

Authors:  Swati Kulkarni; Katarzyna Augoff; Louis Rivera; Brian McCue; Thaer Khoury; Adrienne Groman; Li Zhang; Lili Tian; Khalid Sossey-Alaoui
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

9.  Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.

Authors:  Qian Wu; Li Guo; Fei Jiang; Lei Li; Zhong Li; Feng Chen
Journal:  J Cell Mol Med       Date:  2015-09-28       Impact factor: 5.310

10.  Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.

Authors:  Nagireddy Putluri; Suman Maity; Ramakrishna Kommagani; Ramakrishna Kommangani; Chad J Creighton; Vasanta Putluri; Fengju Chen; Sarmishta Nanda; Salil Kumar Bhowmik; Atsushi Terunuma; Tiffany Dorsey; Agostina Nardone; Xiaoyong Fu; Chad Shaw; Tapasree Roy Sarkar; Rachel Schiff; John P Lydon; Bert W O'Malley; Stefan Ambs; Gokul M Das; George Michailidis; Arun Sreekumar
Journal:  Neoplasia       Date:  2014-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.